Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
ARA-290 Peptide
Erythropoietin-derived peptide researched for neuropathy and tissue repair.
What is ARA-290?
ARA-290 is a neuropathic · immune modulation peptide studied for small-fiber neuropathy and sarcoidosis and diabetic neuropathy. Below is an educational overview of ARA-290 peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
ARA-290 Mechanism of Action
A synthetic 11-amino-acid peptide derived from the erythropoietin molecule. Research indicates it retains the tissue-protective (non-erythropoietic) effects of EPO via the β-common receptor, without stimulating red blood cell production.
ARA-290 Research Areas & Benefits
ARA-290 Dosage & Common Research Protocols
Daily or twice-weekly subcutaneous dosing in neuropathy trials.
Protocols summarized for educational reference from published research. Not dosing guidance.
ARA-290 Studies & Cited Research
ARA-290 in sarcoidosis-associated small-fiber neuropathy
Improved pain scores and corneal nerve fiber density in sarcoidosis patients.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
ARA-290 tissue protective effects
Reviewed non-hematopoietic protective mechanisms via the innate repair receptor.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
ARA-290 Side Effects & Safety Considerations
- •Investigational; not FDA-approved.
- •Does not raise hematocrit like full EPO molecule.
Common questions about ARA-290
More Immune peptides · See all 6
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.